Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Friday, June 30, 2023.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q1 FY2023 (2023-06-30): 194.92%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
109.20%
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Psyence Biomedical Ltd.
Market Cap
$97282.00
Return on Equity (ROE)
N/A
TTM Avg
109.20%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$108729.00
Return on Equity (ROE)
-31722.73%
TTM Avg
-22.71%
3Y Avg
4.16%
5Y Avg
21.87%
Market Cap
$71110.00
Return on Equity (ROE)
-56.04%
TTM Avg
-428.20%
3Y Avg
-266.31%
5Y Avg
-188.29%
Market Cap
$61495.00
Return on Equity (ROE)
N/A
TTM Avg
163.76%
3Y Avg
281.78%
5Y Avg
257.03%
Market Cap
$31083.00
Return on Equity (ROE)
-33.87%
TTM Avg
-18.48%
3Y Avg
-27.44%
5Y Avg
-15.83%
Market Cap
$30509.00
Return on Equity (ROE)
-124.31%
TTM Avg
-250.62%
3Y Avg
35.28%
5Y Avg
30.27%
Market Cap
$6115.00
Return on Equity (ROE)
N/A
TTM Avg
43.59%
3Y Avg
43.03%
5Y Avg
34.44%
Market Cap
$242924.00
Return on Equity (ROE)
-287.31%
TTM Avg
-182.19%
3Y Avg
-117.96%
5Y Avg
-131.39%
Market Cap
$380715.00
Return on Equity (ROE)
-66.30%
TTM Avg
-86.35%
3Y Avg
-89.49%
5Y Avg
-12.24%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Psyence Biomedical Ltd. (PBM) | $97282.00 | N/A | 109.20% | N/A | N/A |
| Silexion Therapeutics Ltd. (SLXN)vs › | $108729.00 | -31722.73% | -22.71% | 4.16% | 21.87% |
| PRF Technologies Ltd. (PRFX)vs › | $71110.00 | -56.04% | -428.20% | -266.31% | -188.29% |
| Akanda Corp. (AKAN)vs › | $61495.00 | N/A | 163.76% | 281.78% | 257.03% |
| Zhongchao Inc. (ZCMD)vs › | $31083.00 | -33.87% | -18.48% | -27.44% | -15.83% |
| Mobile-health Network Solutions Class A Ordinary Shares (MNDR)vs › | $30509.00 | -124.31% | -250.62% | 35.28% | 30.27% |
| NewGenIvf Group Limited (NIVF)vs › | $6115.00 | N/A | 43.59% | 43.03% | 34.44% |
| SciSparc Ltd. (SPRC)vs › | $242924.00 | -287.31% | -182.19% | -117.96% | -131.39% |
| Virax Biolabs Group Limited (VRAX)vs › | $380715.00 | -66.30% | -86.35% | -89.49% | -12.24% |
| Niki BioSolutions, Inc. (NIKI)vs › | $381940.00 | -5.89% | -13.04% | -24.95% | -31.50% |
ROE
N/A
ROA
N/A
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2023-06-30 | 194.92% |
| 2023-03-31 | 335.74% |
| 2022-12-31 | 3.41% |
| 2022-09-30 | 6.32% |
| 2022-06-30 | 5.59% |
| 2022-03-31 | 4.63% |
| 2021-12-31 | 3.47% |
